TITLE

INTERIM DATA SHOWS GOOD RESULTS FOR X-EXCITE VS. VIAGRA

PUB. DATE
May 2011
SOURCE
Worldwide Biotech;May2011, Vol. 23 Issue 5, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Global Health Ventures' therapeutic drug X-Excite was able to meet the three Pharmacokinetics end points after a VData analysis. During the analysis, X-Excite proved that it did not exceed the C max of Viagra and that its T max was lower and better, which proves that it could produce less side effects. Global Health president and chief executive Dr. Hassan Salari said that they are pleased with the interim data and is on to do full blood profiling in Europe. Global Health specializes in drug delivery and formulation.
ACCESSION #
60242737

 

Related Articles

  • From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Wilffert, Bob; Swen, Jesse; Mulder, Hans; Touw, Daan; Maitland-Van der Zee, Anke-Hilse; Deneer, Vera // International Journal of Clinical Pharmacy;Feb2011, Vol. 33 Issue 1, p3 

    im of the review The translation of evidence based medicine to a specific patient presents a considerable challenge. We present by means of the examples nortriptyline, tramadol, clopidogrel, coumarins, abacavir and antipsychotics the discrepancy between available pharmacogenetic information and...

  • Fluvoxamine significantly alters tizanidine pharmacokinetics.  // Reactions Weekly;6/19/2004, Issue 1006, p4 

    Reports on a study conducted by researchers from Finland on the effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of tizanidine. Dosage of fluvoxamine administered to the study's participants; Increase in the pharmacodynamic responses to tizanidine following fluvoxamine...

  • Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. Li, Cheng; Choi, Dong-Hyun; Choi, Jun-Shik // Journal of Pharmacokinetics & Pharmacodynamics;Feb2012, Vol. 39 Issue 1, p99 

    The purpose of this study was to investigate the effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide in rats. The pharmacokinetic parameters of repaglinide and blood glucose concentrations were also determined in rats after oral (0.5 mg/kg) and intravenous (0.2...

  • A novel strategy for physiologically based predictions of human pharmacokinetics. Jones, Hannah M.; Parrott, Neil; Jorga, Karin; Lavé, Thierry; Lavé, Thierry // Clinical Pharmacokinetics;2006, Vol. 45 Issue 5, p511 

    Background: The major aim of this study was to develop a strategy for predicting human pharmacokinetics using physiologically based pharmacokinetic (PBPK) modelling. This was compared with allometry (of plasma concentration-time profiles using the Dedrick approach), in order to...

  • Clinical Pharmacokinetics and Pharmacodynamics of Etravirine. Schöller-Gyüre, Monika; Kakuda, Thomas N.; Raoof, Araz; de Smedt, Goedele; Hoetelmans, Richard M. W. // Clinical Pharmacokinetics;2009, Vol. 48 Issue 9, p561 

    Etravirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of HIV-1 infection. It has a high genetic barrier to the emergence of viral resistance, and maintains its antiviral activity in the presence of common NNRTI mutations. The...

  • Cancer Pharmacogenetics: The Move from Pharmacokinetics to Pharmacodynamics. Hoskins, J. M.; McLeod, H. L. // Current Pharmacogenomics;Mar2006, Vol. 4 Issue 1, p39 

    Drug response is a complex process determined by both genetic and non-genetic factors. Factors that control drug response can be divided into those that affect the systemic distribution and the concentration of drug at its target (pharmacokinetics) and those associated with drug targets and...

  • Determinants of Drug Metabolism in Early Neonatal Life. Allegaert, Karel; van den Anker, John N.; Naulaers, Gunnar; de Hoon, Jan // Current Clinical Pharmacology;Jan2007, Vol. 2 Issue 1, p23 

    Clinical pharmacology intends to predict drug-specific effects and side effects based on pharmacokinetics (i.e. absorption, distribution, metabolism and elimination) and pharmacodynamics (i.e. dose/effect relationship). Developmental pharmacology focuses on the maturational aspects of these...

  • A reduction in between subject variability is not mandatory for selecting a new covariate. Lagishetty, Chakradhar; Vajjah, Pavan; Duffull, Stephen // Journal of Pharmacokinetics & Pharmacodynamics;Aug2012, Vol. 39 Issue 4, p383 

    Population pharmacokinetic-pharmacodynamic analysis involves nonlinear hierarchical modelling where the mean response in a population and the variability in response from different sources are studied. It generally consists of two model hierarchies: a model for residual error and a model for...

  • Drug metabolism. Park, GR // Continuing Education in Anaesthesia, Critical Care & Pain;Dec2001, Vol. 1 Issue 6, p185 

    The article discusses the metabolism of drugs in the body. Drug metabolism is aimed at changing drugs from an active to an inactive molecule. The first phase of the classical pathway of metabolism involves the transfer of molecular oxygen. Genotype, sex, age and hypoxaemia are some of the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics